Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

Babafemi O. Taiwo*, Vincent C. Marconi, Baiba Berzins, Carlee B. Moser, Amesika N. Nyaku, Carl J. Fichtenbaum, Constance A. Benson, Timothy Wilkin, Susan L. Koletar, Jonathan Colasanti, Edward P. Acosta, Jonathan Z. Li, Paul E. Sax

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Abstract

In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There was no emergence of drug resistance in the participant who experienced virologic failure while receiving dolutegravir plus lamivudine. Clinical Trials Registration NCT02263326

Original languageEnglish (US)
Pages (from-to)1794-1797
Number of pages4
JournalClinical Infectious Diseases
Volume66
Issue number11
DOIs
StatePublished - May 17 2018

Keywords

  • 2-drug
  • Dolutegravir
  • lamivudine
  • maintenance therapy

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial'. Together they form a unique fingerprint.

Cite this